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Abstract
Ion Channel-Coupled Receptors (ICCRs) are artificial proteins comprised of a G protein-coupled receptor and a fused ion
channel, engineered to couple channel gating to ligand binding. These novel biological objects have potential use in drug
screening and functional characterization, in addition to providing new tools in the synthetic biology repertoire as synthetic
K
+-selective ligand-gated channels. The ICCR concept was previously validated with fusion proteins between the K
+ channel
Kir6.2 and muscarinic M2 or dopaminergic D2 receptors. Here, we extend the concept to the distinct, longer b2-adrenergic
receptor which, unlike M2 and D2 receptors, displayed barely detectable surface expression in our Xenopus oocyte
expression system and did not couple to Kir6.2 when unmodified. Here, we show that a Kir6.2-binding protein, the N-
terminal transmembrane domain of the sulfonylurea receptor, can greatly increase plasma membrane expression of b2
constructs. We then demonstrate how engineering of both receptor and channel can produce b2-Kir6.2 ICCRs. Specifically,
removal of 62–72 residues from the cytoplasmic C-terminus of the receptor was required to enable coupling, suggesting
that ligand-dependent conformational changes do not efficiently propagate to the distal C-terminus. Characterization of the
b2 ICCRs demonstrated that full and partial agonists had the same coupling efficacy, that an inverse agonist had no effect
and that the stabilizing mutation E122 W reduced agonist-induced coupling efficacy without affecting affinity. Because the
ICCRs are expected to report motions of the receptor C-terminus, these results provide novel insights into the
conformational dynamics of the b2 receptor.
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Introduction
Ion channel-coupled receptors [ICCRs] are protein-based
biosensors created by the covalent assembly of a G Protein-
Coupled Receptor [GPCR] and a potassium channel[1]. In such a
system, the receptor-channel assembly is engineered to optimize
physical interactions between the two proteins so that the
conformational changes induced by ligand binding to the receptor
are transduced into changes in channel gating, resulting in
modification of the recorded ionic current directly correlated with
the ligand concentration. These constructs combine the advan-
tages of the two proteins: 1) Ion channels generate electrical
signals, large enough to permit single molecule detection; 2)
GPCRs recognize chemical ligands with high specificity and
affinity. Applications are envisioned in GPCR drug screening by
integration in existing ion channel screening platforms or in future
microelectronic systems for diagnostic devices or real-time
detectors of chemical compounds.
As an initial proof-of-concept, we created functional ICCRs
using the inward rectifier K
+ channel Kir6.2 and two distinct
model receptors: the muscarinic receptor M2 and the long
dopaminergic receptor D2[1]. These ICCRs, designated M2-K
and D2-K, were obtained by fusing receptor C-terminus to
channel N-terminus. We demonstrated that receptor-channel
coupling could only be achieved after removal of the first 20–25
residues of the channel, without modification of the receptor C-
termini. M2 and D2 receptors are coupled to Gi/o proteins and are
characterized by short cytoplasmic C-termini. To extend the
ICCR concept and examine the impact of a longer receptor C-
terminus, we coupled to Kir6.2 a Gs-protein-coupled receptor with
an extended C-terminus, the human b2-adrenergic receptor
[b2AR].
The b2AR represents one of the most studied GPCRs. It is
involved in smooth muscle (vascular, airway and uterine)
relaxation. Because of its physiological role, the b2-adrenergic
receptor constitutes a target of interest for a wide range of
drugs[2]. Indeed, b-blockers are used for treatment of hyperten-
sion, glaucoma or after a myocardial infarction[3], while b2AR
agonists are widely used to treat asthma and premature prenatal
contractions. Recently, an engineered b2-adrenergic receptor
structure was solved at 2.4 A ˚[4], providing detailed structural
information.
The channel protein that we have used to build ICCRs is
Kir6.2, the pore-forming subunit of the ATP-sensitive potassium
channel (KATP channel), the other regulatory subunit being the
sulfonylurea receptor SUR[5]. The KATP channel is constituted of
4 Kir6.2 subunits, which form a K
+-selective pore, and 4
sulfonylurea receptor [SUR] proteins[6]. Within this octameric
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influence of internal adenine nucleotides and pharmacological
compounds such as sulfonylureas and K-channel-openers[7,8].
Kir6.2 is itself directly inhibited by intracellular ATP through a
unique nucleotide binding pocket presumably made up of the N-
terminal tail of a Kir6.2 subunit and the C-terminal end of the
neighbor[9]. This property of Kir6.2 serves as a simple way to
identify it and adjust its open probability. Among other SUR
regions that interacts with Kir6.2[10], one of the transmembrane
domains of SUR, TMD0, is known to tightly bind to Kir6.2 and to
facilitate its trafficking to the plasma membrane[11,12].
Here, we report the successful engineering and characterization
of b2-based ICCRs. A prerequisite to this project was to find a way
to overcome poor surface expression of b2AR-Kir6.2 fusion
proteins. This was achieved by co-expression of TMD0 of isoform
SUR1 which dramatically increased surface expression of all
constructs through its interactions with Kir6.2. Pharmacological
characterization of b2 ICCRs demonstrated concentration-depen-
dent effects of b-adrenergic agonists and antagonists. In addition,
the amplitude of the agonist-induced signal depended on the
receptor-channel linker length, corroborating previous observa-
tions[1] and demonstrating the crucial role of the receptor C-
terminus in coupling efficiency. We also examined the effect of a
b2AR stabilizing mutation at position 3.41 in the Ballesteros/
Weinstein scheme[13,14] on the communication between receptor
and channel and found that it logically reduced the amplitude of
the agonist responses.
Part of this work has been published in abstract form[15].
Results
Design of b2 ICCRs
Building the original M2 and D2 ICCRs helped delineate the
blueprints for other ICCRs. We therefore used the M2 and D2
ICCRsastemplatesforexpedientdesignofb2 ICCRs.AlthoughM2
and D2 display a low overall sequence similarity of ,30% with
b2AR, the sequence of the H8 helix is well conserved and was used
to unambiguously align the C-terminal extremities of the receptors
(Fig. 1). This alignment shows that the C-terminus of b2AR is much
longer than that of M2 and D2. Reasoning that this long C-terminus
might preclude proper coupling, we constructed three b2-based
ICCRs: one using the full-length receptor, and two comprised of C-
terminal truncated forms of b2AR (b2DC62 and b2DC72), equivalent
in length to the M2 and D2 receptors, respectively. These receptors
were fused to a truncated Kir6.2 lacking its first 25 N-terminal
residues, a modification that was shown to produce the most
efficient coupling in M2 and D2 ICCRs[1]. To designate the
constructs, we use the nomenclature R-K-X-Y, where R is replaced
by the short name of the receptor, K stands for Kir6.2, X and Y are
the number of residues removed from the receptor C-terminus and
channel N-terminus, respectively. The b2 constructs are therefore
named b2-K0–25, b2-K-62-25, and b2-K-72-25.
Optimizing surface expression
Constructs were expressed in Xenopus oocytes and characterized
by the two-electrode voltage clamp technique. As a rough estimate
of surface expression levels, we measured the basal currents, i.e.,
the initial whole-cell currents, (Fig. 2). The three b2 constructs
produced basal currents that were equivalent to those obtained
with non-injected oocytes suggesting no or little expression of
active channels. In an attempt to solve this expression problem, we
engineered ICCRs using the b2(E122 W) mutant. This mutation of
Glu122 to Trp122 at Ballesteros/Weinstein position 3.41[13] has
been shown to enhance the surface expression level of the b2-
adrenergic receptor in insect and mammalian cells by stabilizing
the TM4-TM3-TM5 helix interface[14]. This mutation had no
effect on the basal current of b2-based ICCRs.
It has been demonstrated that N-terminal deletions could favor
cell surface expression of the cannabinoid receptor 1[16] and the
a1D-adrenergic receptor[17]. We therefore tried gradual N-
terminal deletions of the first 10 to 25 residues of b2AR in
construction b2-K-62-25. The data shown in Fig. S1 show that these
modifications did not improve expression. Also shown in Fig. S1
are the disappointing outcomes of using N-terminal and C-
terminal chimera between b2AR and the robustly-expressed M2
receptor.
We then tested the co-expression of TMD0, a 195-residue N-
terminal transmembrane domain of SUR1, known to facilitate
Kir6.2 trafficking[11], with b2-based ICCRs. The resulting basal
current was increased 5-fold for b2-K0–25 and b2-K-62-25 and 7-fold
for b2-K-72-25 compared to the ICCRs expressed alone. Thus, we
found an efficient way to enhance significantly surface expression
levels of the b2-based ICCRs. These results suggest that TMD0
helps the b2-based ICCRs reach the membrane because of its
chaperone role on Kir6.2.
Demonstration of direct receptor-channel coupling
The functionality of the coupling between b2AR (full-length,
DC62, DC72) and Kir6.2 was tested with the b-adrenergic agonist
isoproterenol. We initially verified that isoproterenol had no direct or
receptor-mediated effects on Kir6.2 alone or co-expressed with b2AR
(Fig. 3B). When the fusion proteins where expressed (with TMD0),
b2-K0–25 did not respond to isoproterenol whereas b2-K-62-25 and b2-
K-72-25 were strongly activated (Fig. 3). Isoproterenol responses were
concentration-dependent with no obvious cooperativity (Hill coeffi-
cients ,1). Given the variability in the data, the EC50 of 149 nM for
b2-K-62-25 and 288 nM for b2-K-72-25 were not significantly different
(p=0.31; unpaired Student’s t-test). These values are consistent with
those from other techniques that do not rely on G-protein signalling
such as competitive radioligand binding or fluorescence spectrosco-
py[18,19]. The maximal channel activation was 64% of the basal
current for b2-K-62-25 and 37%forb2-K-72-25, a statisticallysignificant
difference (p=0.018). This change in efficacy without change in
affinity underscores the role of the length of the receptor-channel
linker region in efficient transmission of the ligand-induced b2
conformational change to the channel gate.
We next tested the effect of the antagonist alprenolol at 5 mM
on the isoproterenol-activated current. Alprenolol did not alter the
current generated by the isoproterenol-insensitive construct b2-
K0–25 but it caused a complete block of isoproterenol activation of
b2-K-62-25 and b2-K-72-25 (Fig. 4). This block could not be washed
out after several minutes, probably because we used a relatively
high alprenolol concentration. These results confirmed the
specificity of isoproterenol effect on the b2 adrenergic receptor.
Partial and inverse agonists
Full agonists can cause maximal activation of the receptor
whereas partial agonists cause an activation which remains less
than maximal even at saturating concentrations. It is thought that
full and partial agonists of the b-adrenoceptor do not trigger the
same conformational changes in the receptor. As a comparison
with the full agonist isoproterenol, we therefore assayed the partial
agonist salbutamol on construct b2-K-62-25. As shown in Fig. 5,
salbutamol strongly activated b2-K-62-25. The maximal activation,
78% of the basal current at 50 mM, was larger, though not
significantly (p=0.12) than that achieved by isoproterenol, 63% at
50 mM. The concentration dependence was not as steep with a
Hill slope of 0.64 compared to 1.04 for isoproterenol. Although
b2-Adrenergic Ion-Channel Coupled Receptors
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distinct modes of action for partial and full agonists[20].
Inverse agonists, thought to target the agonist binding site,
downregulates the receptor by blocking its constitutive activity. We
examined the effects of the inverse agonist timolol[21]. At
concentrations up to 50 mM, timolol did not produce any significant
change in the electrical signal from either b2-K-62-25 or b2-K-72-25
(Fig. 5C). This lack of effects suggests that binding of timolol does
not induce a large conformational change in the receptor.
Another possibility could be that the ICCRs are partly cleaved
and that we could have an unresponsive Kir6.2 breakdown
product responsible for the high basal current together with a
responsive full-length fusion construct with no basal current. In
that case, an already inactive construct could not possibly be
further inhibited by timolol. This hypothesis is highly improbable
because 1) we have never detected any breakdown products by
Western blot in other similar fusion constructs not included in the
present work, and 2) Fig. S2 shows that Kir6.2 + TMD0 produces
a basal current that is barely detectable.
A stabilizing mutation alters coupling
To further show that ICCR systems can be used as a functional
characterization tool, we set out a study on the E122 W b2AR
mutant described above. As described in Fig. 6, for construct b2-K-
62-25, mutation E122 W appeared to reduce the amplitude of the
agonist-induced signal (from 63.5% to 51% at maximum
activation) and to increase dissociation constant (from 149 nM
to 247 nM) but these effects did not reach statistical significance
(p=0.12 for amplitudes; p=0.24 for affinities). The mutation had
a stronger effect on construct b2-K-72-25 since maximal activation
decreased from 37% to 11%, a statistically significant change
(p=0.017). In that case, affinities could not be compared because
the activation of the b2(E122 W)-K-72-25 was too weak for proper
fitting. These results could be explained by the fact that
stabilization of the TM4-TM3-TM5 helix interface[14] induces
less important conformational change in b2AR upon ligand
Figure 1. Design strategy of b2-based Ion Channel-Coupled Receptors. ICCRs were formed by covalent linkage of GPCRs C-termini to Kir6.2
channel N-terminus. Helix H8 and b-bridge b1 are predicted from the b2AR (PDB code: 2RH1) and chimeric Kir3.1 (PDB code: 2QKS) structures,
respectively. M2-K0–25 and D2-K0–25 are the ICCRs previously shown to be functional with 25 residues deleted from the Kir6.2 N-terminus. We used the
same Kir6.2 deletion to build b2 ICCRs, with additional deletions in the receptor C-terminus. b2-K0–25 ICCR contains the full-length receptor, b2-K-62-25
and b2-K-72-25 are based on the b2AR deleted of 62 and 72 residues in its C-terminal domain to match the lengths of M2 and D2, respectively.
doi:10.1371/journal.pone.0018226.g001
Figure 2. TMD0 of SUR boosts expression of b2-based ICCRs.
Basal currents are the whole-cell currents measured in the first minute
of TEVC recording from unstimulated Xenopus oocytes. E122 W is a
mutation of residue 122 of b2AR from Glu to Trp reported to increase b2
surface expression.TMD0 is the first transmembrane domain of the
sulfonylurea receptor SUR1, a physiological partner of Kir6.2. *P,0.05
and **P,0.00001 represent significant differences from the basal
current measured in non-injected oocytes.
doi:10.1371/journal.pone.0018226.g002
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interface and the Trp ring may interact with Pro211
5.50 partially
decreasing TM5 flexibility. Since TM5 is assumed to serve as an
intermediate between the TM1-4 structural core and TM6-7[22],
we can imagine that the quality of the transmission of
conformational change may be constrained by such mutation.
This might lead to a less efficient communication with Kir6.2
resulting in decreased amplitude of the response.
Discussion
Using the ICCR concept established with M2 and D2
receptors[1], we have used the b2-adrenergic receptor to create
syntheticligand-gated K
+ channelssensitivetob-adrenergicligands.
Surface expression enhancement by an accessory Kir6.2-
binding protein
A recurrent difficulty with recombinant membrane proteins is
the low density of proteins that reach the plasma membrane.
Although Xenopus oocytes are very tolerant in that respect,
expression of the b2-Kir6.2 fusion constructs produced no
discernible electrophysiological signals. Suspecting a trafficking
impediment, we searched for ways to enhance surface expression.
It is known that Kir6.2 possess a C-terminal endoplasmic-
reticulum retention signal[23] but removal of this signal in M2
ICCRs did not augment surface expression[1]. The mutation
E122 W in b2AR, reported to increase surface expression[14] was
also not beneficial. The solution came from the KATP channel.
That channel is a complex of Kir6.2 and the protein SUR.
Association of SUR to Kir6.2 is known to be mediated in large
part by its N-terminal transmembrane domain TMD0, a ,200-
residue alpha-helical region that binds to Kir6.2 by itself and can
promote its targeting to the surface membrane[11]. When the
TMD0 domain of the sulfonylurea receptor isoform SUR1 was co-
expressed with the various b2-Kir6.2 constructs, large K
+ currents
could be recorded indicative of the presence of active Kir6.2 at the
oocyte surface. This discovery was the key to the pursuit of the
project. It suggests that, in the tetrameric b2-Kir6.2 complexes,
there is ample space for TMD0 to bind to Kir6.2 and to act as a
chaperone to promote proper membrane targeting.
Functional b2 ICCRs
The b2 ICCRs were engineered by covalent linkage of b2AR to
the Kir6.2 channel to promote physical interactions between the
two proteins. Functional coupling could only be achieved after
removal of 25 residues from the Kir6.2 N-terminus, as in previous
Figure 3. Receptor-channel coupling in b2 ICCRs: response to the agonist isoproterenol. (A) Representative TEVC recordings from Xenopus
oocytes expressing each b2 ICCR and TMD0. Membrane potential was 250 mV. Dashed lines indicate the baseline of Ba
2+-sensitive currents. (B)
Concentration-effect curves for isoproterenol measured in oocytes co-expressing the indicated proteins. Kir6.2DC36 is deleted of its last 36 residues to
allow surface expression of the channel alone. Values are average of 5–14 measurements. Smooth lines correspond to Hill equations fits with EC50 in
parentheses and h=1.07 for b2-K-62-25 and 1 for b2-K-72-25.
doi:10.1371/journal.pone.0018226.g003
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whereas M2 and D2 ICCRs used unmodified receptors. These
residues which are not resolved in crystallographic structures[4]
probably form flexible elements[24] that dampen transmission of
mechanical perturbations from receptor to channel. The depen-
dence of responses on the length of the receptor-channel argues
strongly for a direct, physical interaction between receptor and
channel. We also verified the lack of detectable G-protein
dependent modulation of Kir6.2 by b2AR in control experiments
where receptor and channel were coexpressed as separate proteins.
Furthermore, b2AR is predominantly Gs-coupled, the M2 receptor
is Gi-coupled, but both produce similar effects when fused to
Kir6.2.
ICCRs as conformational motion detectors
Constructs b2-K-62-25 and b2-K-72-25 (+TMD0) detected the
presence of agonists with dose-dependent correlation, in direct,
real-time and label-free conditions. The affinity measured for the
full agonist isoproterenol matched those obtained by radioligand
assays[14,19] as well as spectroscopy assays that, like ICCRs,
directly measure conformational changes[18]. The effect of the
partial agonist salbutamol was similar to that of isoproterenol
although it showed lower affinity as expected. Isoproterenol and
salbutamol have been shown to induce distinct conformations. In
particular, evidence suggests that both disrupt the cytoplasmic
ionic lock while only isoproterenol uses the rotamer toggle
switch[25]. The similarity of the responses elicited by salbutamol
and isoproterenol suggests that the conformational changes
detected by the channel could be related to the ionic lock rather
than the rotamer toggle switch[25]. Because by construction
ICCRs report on the motion of the GPCR C-terminus, this would
imply that disruption of the ionic lock triggers a conformational
change in the C-terminus.
The effect of the antagonist alprenolol was easily detectable by
abolition of the agonist-induced increase of the ionic current. If
alprenolol did not change basal signal, inverse agonists are
expected to reduce basal activity and elicit signals in absence of
agonists. In the ICCR assay, the inverse agonist timolol produced
no significant signal. Although this observation could result from
an intrinsically low basal activity of b2AR due to the expression
system or the fusion to Kir6.2, it shows that binding of timolol does
not induce any detectable conformational change of the C-
terminus. Such conclusion is consistent with a recent crystallo-
graphic study[26] showing only very small differences between the
antagonist-bound and inverse-agonist-bound structures of b2AR.
Thus, beside the obvious use of ICCRs in drug screening, they
could be valuable to dissect the conformational changes induced
by ligands. We provided an additional example of such use by
demonstrating that a stabilizing mutation, E122 W3.41[14],
reduced the amplitude of the ICCR response in line with its
purported attenuation of conformational changes.
Figure 4. Effect of a b-adrenergic antagonist on b2 ICCRs. (A) TEVC recordings showing antagonist effect of 5 mM alprenolol during addition of
0.5 mM isoproterenol on b2-K0–25, b2-K-62-25 and b2-K-72-25.( B) Change in whole-cell currents evoked by isoproterenol before and after addition of
5 mM alprenolol. **P,0.00075 indicates a significant inhibition induced by alprenolol.
doi:10.1371/journal.pone.0018226.g004
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e18226Figure 5. Effect of a b2AR partial agonist on b2-K-62-25. Concentration-effect curves for salbutamol measured in oocytes co-expressing the
indicated proteins. Values are average of 3-7 measurements. The smooth line is a Hill equation fit to the b2-K-62-25+TMD0 data with EC50 = 452 nM
and h=0.6. Data obtained with the unfused Kir6.2 as a control could not be fitted.
doi:10.1371/journal.pone.0018226.g005
b2-Adrenergic Ion-Channel Coupled Receptors
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ICCRs demonstrate that, provided a GPCR is tightly associated
with an ion channel, it can directly modulate channel gating
possibly through mechanical forces transmitted by its C-terminal
tail. Did evolution overlook this seemingly trivial possibility of
using localized modulation in addition to the more indiscriminate
second-messenger pathways? Probably not, as there is solid
evidence that receptors and channels can form stable com-
plex[27–29]. Channel modulation via the C-terminal tail of
GPCRs has been reported for 2 couples, GABAA channel/
dopamine D5 receptor[30] and NMDA channel/dopamine D1
receptor[31]. ICCRs could provide a model for these interactions
as well as for others involving Kir channels[32].
b-adrenergic ligand-activated K
+ channels
Like traditional ligand-gated channels such as the cationic
nicotinic acetylcholine receptor or the anionic GABAA recep-
tor[33], b2 ICCRs incorporates in a single polypeptide chain a
binding site for a specific signaling molecule and an ion-selective
pore that are allosterically linked. They possess, however, the
unique features among ligand-gated channels of being activated by
b-adrenergic signals and of being selective for potassium ions. One
may envision that these ICCRs could be used as novel regulatory
elements in synthetic biology as well as therapeutic tools. Such use
is of course remote and would require to augment trafficking
efficiency to avoid using accessory proteins such as TMD0 and
optimize response efficacy so that channels are closed at rest and
open upon stimulation like existing ligand-gated channels. This
would require protein engineering that is now complex but could
become more straightforward as determinants of membrane
protein trafficking and of channel gating are clarified.
Materials and Methods
Molecular biology
Experiments were conducted as previously described[1]. In this
work, we used mouse Kir6.2 (Genbank D50581)[34], human
b2-adrenergic receptor (Genbank NM_000024.3), hamster
TMD0(SUR1)-F195[11,35], mouse Kir6.2DC36[36]. The b2-K0–25
fusion was obtained by replacing the muscarinic M2 receptor gene
in M2-K0–25 cloned in the Xenopus oocyte expression vector
pGEMHE[1]. Insertion of the b2AR gene and deletion of the M2
gene was performed using a two-step PCR. In the first PCR
reaction, the b2-adrenergic gene was amplified from its original
pCMV vector using hybrid primers complementary to the
b2-adrenergic sequence 39 extremities and to the flanking regions
of the insertion site in the M2-Kir6.2_ pGEMHE. The products of
this reaction were gel-purified (QIAquick Gel Extraction Kit,
Qiagen) andservedasprimersfora secondPCRwithM2-K0–25asa
template, yielding b2-K0–25_pGEMHE. Alignments of the M2,D 2,
and b2 receptor sequences with ClustalX[37] were adjusted
manually to position conserved helix H8. The unstructured C-
terminal region downstream of H8 was longer in the b2AR by 62
and 72 amino acids compared to M2 and D2, respectively (Fig. 1).
To matchthelengths of M2 and D2, additional b2-Kconstructswith
shorter b2AR C-termini were obtained in a single-step PCR using
the b2-K0–25 construct as a template and hybrid oligonucleotides
flanking the deleted region[38]. Mutation E122 W was introduced
in each ICCR in a single-step PCR with oligonucleotides
incorporating the mutation. Reagents and conditions were from
the QuikChange site-directed mutagenesis kit (Agilent Technolo-
gies). Positive clones were identified by restriction enzyme profiling
and verified by sequencing the full open reading frame.
After DNA amplification, constructs were linearized and
mRNAs synthesized using the T7 mMessage mMachine Kit
(Ambion). mRNAs were purified either by standard phenol:chloro-
form extraction or using the MEGAclear Purification Kit
(Ambion), and quantified by agarose-gel electrophoresis and
spectrophotometry.
Electrophysiological recordings
Animal handling and experiments fully conformed with French
regulations and were approved by local governmental veterinary
services (authorization no. 38-08-10 from the Ministe `re de
l’Agriculture, Direction des Services Ve ´te ´rinaires to Michel
Vivaudou). Oocytes were surgically removed from Xenopus laevis
and defolliculated by three 30 min-incubations in 2 mg.ml
21 type
1A collagenase solution at 19uC. Stage V and VI oocytes were
microinjected with 50 nl of RNase-free water containing one or a
mixture of the following quantities of RNA: b2-Kir6.2, 5 ng;
Kir6.2DC36, 2 ng; TMD0(SUR1)-F195, 1 ng. Microinjected oo-
cytes were incubated for .2 days at 19uC in Barth’s solution (in
mM: 1 KCl, 0.82 MgSO4, 88 NaCl, 2.4 NaHCO3, 0.41 CaCl2,1 6
Hepes, pH 7.4) supplemented with 100 U.ml
21 penicillin, strep-
Figure 6. The stabilizing mutation E122 W weakens agonist-induced channel responses. (A) Location of Glu122 (in red) in the b2-
adrenergic receptor structure. (B) Concentration-effect curves of isoproterenol on b2-K-62-25 and b2-K-72-25, unmodified (WT) and harboring mutation
E122 W (all co-expressed with TMD0). Values are average of 5–14 measurements. Hill equation fits, represented as smooth lines, yielded EC50 of
149 nM, 247 nM, and 288 nM for b2-K-62-25, b2(E122 W)-K-62-25, and b2-K-72-25, respectively. h was 1.07, 1, and 1.18.
doi:10.1371/journal.pone.0018226.g006
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Sigma-Aldrich. Whole-cell currents were recorded with the two-
electrode voltage clamp (TEVC) technique using a GeneClamp
500 amplifier (Molecular Devices). Microelectrodes were filled
with 3 M KCl and oocytes were bathed in the following solution
(in mM): 91 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 0.3 niflumic acid
(to block endogenous Cl
- currents), pH 7.4. The TEVC voltage
protocol consisted of 500-ms steps to -50, 0 and +50 mV – during
which current was measured – separated by 5 s at a holding
potential of 0 mV. The values shown in the figures are those
recorded at 250 mV.
Data analysis
Basal current was measured while oocytes were in standard bath
solution during the first minute of recording. Ba
2+ (3 mM) was
used as a generic potassium-channel blocker to establish the
amount of exogenous current, designated as Ba
2+-sensitive current
and calculated by subtracting from all measured values the value
measured at the end of an experiment after application of 3 mM
Ba
2+. All values of current reported here refer to Ba
2+-sensitive
currents. Changes in Ba
2+-sensitive currents by effectors were
calculated with respect to the value measured before application.
The points at which the current were measured on the current
traces are indicated by arrows in the figures. For the concentra-
tion-response data, obtained by sequential application of increas-
ing agonist concentrations, changes in current were calculated
only with respect to the current before application of the initial,
lowest concentration.
Average values are presented as mean6s.e.m. Non-linear least-
square curve-fitting was carried out with Origin 8 software
(OriginLab) using a standard Hill equation:
f(x)=Max/[1 + (EC50/x)
h]
where x is the concentration of a ligand, Max the asymptotical
maximal effect, EC50 the concentration for half-maximal effect,
and h the Hill coefficient. The fits shown in the figures were
performed using average data. For statistical analysis of param-
eters Max and EC50 (using Origin 8 software), individual dose-
response data from each oocyte tested were fitted using the above
equation with h=1 to obtain a set of values of Max and EC50 for
each construct and ligand. Statistical significance for these
parameters and for other experimental data was established with
unpaired two-tailed Student t-tests and is indicated as p-values in
the text.
Supporting Information
Figure S1 Expression levels of various b2-K-62-25 constructs
designed in an attempt to improve surface expression. The basal
currents, whole-oocyte currents recorded in absence of agonist are
taken as an indicator of the number of active channels at the cell
surface. DN10, DN15, DN20, and DN25 designate constructs
based on b2-K-62-25 with the first N-terminal 10, 15, 20, and 25
residues of b2AR deleted. Nt(M2)DN28 is a b2-K-62-25 chimera
where the extracellular N-terminal of b2AR (28 residues) has been
replaced by that of the M2 receptor (18 residues). Ct(M2) is a b2-
K-62-25 where the intracellular C-terminal of b2ARDC62
(residues 326 to 352) has been replaced by that of the M2
receptor (residues 440 to 466).
(PDF)
Figure S2 Comparison of the expression levels of Kir6.2, alone
or fused to b2, coexpressed with TMD0. The basal currents,
whole-oocyte currents recorded in absence of agonist are taken as
an indicator of the number of active channels at the cell surface.
(DOC)
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